Study details
Enrolling now
Dendritic Cell Vaccine Trial
H. Lee Moffitt Cancer Center and Research Institute
NCT IDNCT05809752ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
18
Study length
about 2.6 years
Ages
18+
Locations
3 sites in FL, NY
About this study
This trial is testing a new vaccine, Dendritic Cell Vaccine (DCV), to see how it works in people with breast cancer and leptomeningeal disease. The goal is to find the safest dose of this vaccine.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Dendritic Cell Vaccine
PhasePhase 1
DrugDendritic Cell Vaccine
Routeinjection
Primary goalMaximum Tolerated Dose of Intrathecal Dendritic Cell Vaccine
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
vaccine
Drug routes
injection
Endpoints
Primary: Maximum Tolerated Dose of Intrathecal Dendritic Cell Vaccine
Secondary: Overall Survival, Progression Free Survival
Body systems
Oncology